Evidence map›Paper›PMID 26846107›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy.

Dong Wang, Guangyu An, Shengzhi Xie, Yajuan Yao, Guosheng Feng

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Heterogeneity of monocytes in cancer.American journal of cancer research · 2025
    Review
  10. Radiation Therapy and Myeloid-Derived Suppressor Cells: Breaking Down Their Cancerous Partnership.International journal of radiation oncology, biology, physics · 2024
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Irradiation immunity interactions.Journal of medical imaging and radiation oncology · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Dong WangDepartment of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Guangyu AnDepartment of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Shengzhi XieDepartment of Oncology, General Hospital of Chinese People's Armed Police Forces, Beijing, 100039, China.
Yajuan YaoDepartment of Oncology, Tong-Liao City Hospital of Inner Mongolia, Tong-Liao, 028000, China.
Guosheng FengDepartment of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China. geng_cmu@126.com.
Beijing Chao-Yang Hospital · CNCapital Medical University · CNChinese People's Armed Police Force

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid-derived suppressor cells (MDSCs) are key player in mediating systemic immunosuppression, and their accumulation and expansion in the periphery and tumor have been iteratively observed in patients with various types of cancer. It has been reported that CD14(+)HLA-DR(-/low) MDSCs are increased in hepatocellular carcinoma (HCC) patients; however, the clinical significance of MDSC alteration in HCC patients after treatment is poorly studied. In this study, we examined the frequency of MDSCs in 92 HCC patients, 14 chronic liver disease patients without HCC, and 22 healthy controls by flow cytometric analysis. The associations between the clinical features and the frequency of MDSCs were analyzed. In particular, we further examined the prognostic impact of MDSCs on the overall survival of HCC patients receiving radiation therapy. The frequency of MDSCs in HCC patients was significantly increased and correlated with tumor stage, size, burden, and Child-Pugh classification but not with biochemical parameters of liver function. In HCC patients who received radiation therapy, the frequency of MDSCs after treatment significantly decreased and was inversely correlated with overall survival time. In multivariate analysis, only post-treatment MDSC ratio and Child-Pugh classification were correlated with the prognosis of HCC patients. Patients with a high frequency of MDSCs after radiotherapy should be closely followed, and the inhibition of MDSCs may improve the prognosis of patients.

Indexed as

Radiotherapy, ConformalRadiotherapy, Intensity-ModulatedAdultAgedCarcinoma, HepatocellularFemaleHLA-DR AntigensHumansKaplan-Meier EstimateLipopolysaccharide ReceptorsLiver NeoplasmsMaleMiddle AgedMyeloid-Derived Suppressor CellsPrognosisTreatment OutcomeHLA-DR AntigensLipopolysaccharide ReceptorsHepatocellular carcinomaMyeloid-derived suppressor cellsOverall survivalRadiation therapy

Identifiers

PMID26846107
OpenAlexW2261022107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.